Skip to main content
SpringerLink
Log in

Epigenetic Alterations in Primary Prostate Cancer

  • Chapter
  • First Online:
Precision Molecular Pathology of Prostate Cancer

Part of the book series: Molecular Pathology Library ((MPLB))

Abstract

Epigenetics defines the molecular mechanisms that alter gene function and regulation without affecting the genome sequence. It is now well documented that initiation and progression of cancer are caused by genetic alterations and also by aberrant changes to the cancer epigenetic landscape. Understanding epigenetic abnormalities involved in carcinogenesis has great potential for a new mode of molecular pathology in cancer detection and treatment in all types of cancer, including prostate cancer. In this chapter, we review the most common epigenetic aberrations identified in prostate cancer as well as their biological and clinical relevance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Holliday R. Epigenetics: a historical overview. Epigenetics. 2006;1(2):76–80.

    Article  PubMed  Google Scholar 

  2. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.

    Article  CAS  PubMed  Google Scholar 

  4. Shah S, McRae AF, Marioni RE, Harris SE, Gibson J, Henders AK, et al. Genetic and environmental exposures constrain epigenetic drift over the human life course. Genome Res. 2014;24(11):1725–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361(9360):859–64.

    Article  PubMed  Google Scholar 

  6. Nelson WG, Demarzo AM, Yegnasubramanian S. The diet as a cause of human prostate cancer. Cancer Treat Res. 2014;159:51–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lin PC, Giannopoulou EG, Park K, Mosquera JM, Sboner A, Tewari AK, et al. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia. 2013;15(4):373–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17(3):330–9.

    Article  CAS  PubMed  Google Scholar 

  9. Arand J, Spieler D, Karius T, Branco MR, Meilinger D, Meissner A, et al. In vivo control of CpG and non-CpG DNA methylation by DNA methyltransferases. PLoS Genet. 2012;8(6):e1002750.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462(7271):315–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tomizawa S, Kobayashi H, Watanabe T, Andrews S, Hata K, Kelsey G, et al. Dynamic stage-specific changes in imprinted differentially methylated regions during early mammalian development and prevalence of non-CpG methylation in oocytes. Development. 2011;138(5):811–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ziller MJ, Muller F, Liao J, Zhang Y, Gu H, Bock C, et al. Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet. 2011;7(12):e1002389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Cho NY, Kim JH, Moon KC, Kang GH. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch. 2009;454(1):17–23.

    Article  CAS  PubMed  Google Scholar 

  14. Yang B, Sun H, Lin W, Hou W, Li H, Zhang L, et al. Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry. Urol Oncol. 2011;31(5):628–34.

    Article  CAS  PubMed  Google Scholar 

  15. Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J, et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet. 2005;156(1):31–6.

    Article  CAS  PubMed  Google Scholar 

  16. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol. 2007;211(3):269–77.

    Article  CAS  PubMed  Google Scholar 

  17. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008;68(21):8954–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R, et al. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer. 2002;35(1):58–65.

    Article  CAS  PubMed  Google Scholar 

  19. Jarrard DF, Bussemakers MJ, Bova GS, Isaacs WB. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin Cancer Res. 1995;1(12):1471–8.

    CAS  PubMed  Google Scholar 

  20. Bhusari S, Yang B, Kueck J, Huang W, Jarrard DF. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate. 2011;71(15):1621–30.

    Article  CAS  PubMed  Google Scholar 

  21. Cho B, Lee H, Jeong S, Bang YJ, Lee HJ, Hwang KS, et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun. 2003;307(1):52–63.

    Article  CAS  PubMed  Google Scholar 

  22. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T, et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 2005;11(16):5793–801.

    Article  CAS  PubMed  Google Scholar 

  23. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res. 2005;11(3):1028–36.

    CAS  PubMed  Google Scholar 

  24. Pakneshan P, Xing RH, Rabbani SA. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J. 2003;17(9):1081–8.

    Article  CAS  PubMed  Google Scholar 

  25. Wang Q, Williamson M, Bott S, Brookman-Amissah N, Freeman A, Nariculam J, et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene. 2007;26(45):6560–5.

    Article  CAS  PubMed  Google Scholar 

  26. Kikuchi A, Yamamoto H, Sato A, Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf). 2012;204(1):17–33.

    Article  CAS  Google Scholar 

  27. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011;60(4):753–66.

    Article  CAS  PubMed  Google Scholar 

  28. Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000;60(21):5941–5.

    CAS  PubMed  Google Scholar 

  29. Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res. 2003;9(7):2673–7.

    CAS  PubMed  Google Scholar 

  30. Jeronimo C, Usadel H, Henrique R, Silva C, Oliveira J, Lopes C, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002;60(6):1131–5.

    Article  PubMed  Google Scholar 

  31. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem. 2004;91(3):540–52.

    Article  CAS  PubMed  Google Scholar 

  32. Devaney J, Stirzaker C, Qu W, Song JZ, Statham AL, Patterson KI, et al. Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers. Cancer Epidemiol Biomark Prev. 2011;20(1):148–59.

    Article  CAS  Google Scholar 

  33. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23(27):6569–75.

    Article  CAS  PubMed  Google Scholar 

  34. Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, et al. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate. 2007;67(4):427–32.

    Article  CAS  PubMed  Google Scholar 

  35. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004;10(24):8472–8.

    Article  CAS  PubMed  Google Scholar 

  36. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 2004;202(2):233–40.

    Article  CAS  PubMed  Google Scholar 

  37. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002;62(12):3498–502.

    CAS  PubMed  Google Scholar 

  38. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene. 2002;21(44):6835–40.

    Article  CAS  PubMed  Google Scholar 

  39. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64(6):1975–86.

    Article  CAS  PubMed  Google Scholar 

  40. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC, et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res. 2005;11(18):6582–8.

    Article  CAS  PubMed  Google Scholar 

  41. Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Muller SC, von Rucker A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol. 2007;51(3):665–74. discussion 74

    Article  CAS  PubMed  Google Scholar 

  42. Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res. 2006;4(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  43. Woodson K, Gillespie J, Hanson J, Emmert-Buck M, Phillips JM, Linehan WM, et al. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate. 2004;60(1):25–31.

    Article  CAS  PubMed  Google Scholar 

  44. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol. 2001;159(5):1815–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Nelson WG, De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ, et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci. 2001;952:135–44.

    Article  CAS  PubMed  Google Scholar 

  46. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate. 2012;72(11):1248–61.

    Article  PubMed  CAS  Google Scholar 

  47. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene. 1999;18(6):1313–24.

    Article  CAS  PubMed  Google Scholar 

  48. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res. 2001;7(9):2727–30.

    CAS  PubMed  Google Scholar 

  49. Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader M, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology. 2001;58(3):335–8.

    Article  CAS  PubMed  Google Scholar 

  50. Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007;13(6):1720–5.

    Article  CAS  PubMed  Google Scholar 

  51. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, Heukamp LC, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology. 2008;71(1):161–7.

    Article  PubMed  Google Scholar 

  52. Baden J, Adams S, Astacio T, Jones J, Markiewicz J, Painter J, et al. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J Urol. 2011;186(5):2101–6.

    Article  PubMed  Google Scholar 

  53. Aitchison A, Warren A, Neal D, Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate. 2007;67(6):638–44.

    Article  CAS  PubMed  Google Scholar 

  54. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci. 2007;120(Pt 19):3327–35.

    Article  CAS  PubMed  Google Scholar 

  55. Chen Y, Li J, Yu X, Li S, Zhang X, Mo Z, et al. APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis. Eur J Hum Genet. 2013;21(9):929–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, et al. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer. Urol Oncol. 2011;29(6):682–9.

    Article  CAS  PubMed  Google Scholar 

  57. Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, et al. A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori. 1998;84(1):87–9.

    CAS  PubMed  Google Scholar 

  58. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol. 2005;23(17):3897–905.

    Article  CAS  PubMed  Google Scholar 

  59. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103(5):1635–40.

    Article  CAS  PubMed  Google Scholar 

  60. Perry AS, Watson RW, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol. 2010;7(12):668–80.

    Article  CAS  PubMed  Google Scholar 

  61. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Gehring M, Reik W, Henikoff S. DNA demethylation by DNA repair. Trends Genet. 2009;25(2):82–90.

    Article  CAS  PubMed  Google Scholar 

  63. Sanz LA, Kota SK, Feil R. Genome-wide DNA demethylation in mammals. Genome Biol. 2010;11(3):110.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol. 2010;11(9):607–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. 2013;14(6):341–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Szulwach KE, Li X, Li Y, Song CX, Han JW, Kim S, et al. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS Genet. 2011;7(6):e1002154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Stroud H, Feng S, Morey Kinney S, Pradhan S, Jacobsen SE. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol. 2011;12(6):R54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Yu M, Hon GC, Szulwach KE, Song CX, Zhang L, Kim A, et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell. 2012;149(6):1368–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget. 2011;2(8):627–37.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2013;32(5):663–9.

    Article  CAS  PubMed  Google Scholar 

  72. Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep. 2012;2(3):568–79.

    Article  CAS  PubMed  Google Scholar 

  73. Perez C, Martinez-Calle N, Martin-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, et al. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One. 2012;7(2):e31605.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Bolton EM, Tuzova AV, Walsh AL, Lynch T, Perry AS. Noncoding RNAs in prostate cancer: the long and the short of it. Clin Cancer Res. 2014;20(1):35–43.

    Article  CAS  PubMed  Google Scholar 

  75. Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int. 2013;1(1):3–9.

    Article  PubMed  Google Scholar 

  76. Walsh AL, Tuzova AV, Bolton EM, Lynch TH, Perry AS. Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'? Trends Mol Med. 2014;20(8):428–36.

    Article  CAS  PubMed  Google Scholar 

  77. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol. 2009;41(1):87–95.

    Article  CAS  PubMed  Google Scholar 

  78. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008;27(12):1788–93.

    Article  CAS  PubMed  Google Scholar 

  79. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166–76.

    CAS  PubMed  Google Scholar 

  80. Valdes-Mora F, Clark SJ. Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene. 2015;34(13):1609–18.

    Article  CAS  PubMed  Google Scholar 

  81. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3):608–16.

    Article  CAS  PubMed  Google Scholar 

  83. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106(4):768–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer. 2010;17(1):F1–17.

    Article  CAS  PubMed  Google Scholar 

  85. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA. 2008;14(3):417–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res. 2013;73(3):1232–44.

    Article  CAS  PubMed  Google Scholar 

  87. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69(8):3356–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014;33(21):2790–800.

    Article  CAS  PubMed  Google Scholar 

  89. Forno I, Ferrero S, Russo MV, Gazzano G, Giangiobbe S, Montanari E, et al. Deregulation of MiR-34b/Sox2 predicts prostate cancer progression. PLoS One. 2015;10(6):e0130060.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene. 2008;27(31):4373–9.

    Article  CAS  PubMed  Google Scholar 

  91. Yang CH, Yue J, Fan M, Pfeffer LM. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010;70(20):8108–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69(6):2287–95.

    Article  CAS  PubMed  Google Scholar 

  93. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9.

    Article  CAS  PubMed  Google Scholar 

  96. Brunner AL, Beck AH, Edris B, Sweeney RT, Zhu SX, Li R, et al. Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol. 2012;13(8):R75.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29(8):742–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013;500(7464):598–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Beckedorff FC, Ayupe AC, Crocci-Souza R, Amaral MS, Nakaya HI, Soltys DT, et al. The intronic long noncoding RNA ANRASSF1 recruits PRC2 to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet. 2013;9(8):e1003705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol. 2013;190(6):2278–87.

    Article  CAS  PubMed  Google Scholar 

  101. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014;74(6):1651–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, et al. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene. 2004;23(2):605–11.

    Article  CAS  PubMed  Google Scholar 

  104. Chung S, Nakagawa H, Uemura M, Piao L, Ashikawa K, Hosono N, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011;102(1):245–52.

    Article  CAS  PubMed  Google Scholar 

  105. Wilusz JE, Freier SM, Spector DL. 3′ end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA. Cell. 2008;135(5):919–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49(13):2949–59.

    Article  CAS  PubMed  Google Scholar 

  107. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8–15. discussion -6

    Article  CAS  PubMed  Google Scholar 

  108. Hessels D, Schalken JA. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009;6(5):255–61.

    Article  CAS  PubMed  Google Scholar 

  109. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54(5):1081–8.

    Article  PubMed  Google Scholar 

  110. Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. Nat Rev Urol. 2011;8(3):123–4.

    Article  PubMed  Google Scholar 

  111. Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014;5:5383.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013;45(11):1392–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell. 2004;116(2):259–72.

    Article  CAS  PubMed  Google Scholar 

  114. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074–80.

    Article  CAS  PubMed  Google Scholar 

  115. Chi P, Allis CD, Wang GG. Covalent histone modifications – miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10(7):457–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′-deoxycytidine. Cancer Res. 2002;62(22):6456–61.

    CAS  PubMed  Google Scholar 

  117. Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007;67(22):10657–63.

    Article  CAS  PubMed  Google Scholar 

  118. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391–400.

    Article  CAS  PubMed  Google Scholar 

  119. Behbahani TE, Kahl P, von der Gathen J, Heukamp LC, Baumann C, Gutgemann I, et al. Alterations of global histone H4K20 methylation during prostate carcinogenesis. BMC Urol. 2012;12:5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomark Prev. 2010;19(10):2611–22.

    Article  CAS  Google Scholar 

  121. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005;435(7046):1262–6.

    Article  CAS  PubMed  Google Scholar 

  122. Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate. 2010;70(1):61–9.

    Article  CAS  PubMed  Google Scholar 

  123. Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS, et al. Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol. 2010;12(3):235–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet. 2006;38(5):540–9.

    Article  CAS  PubMed  Google Scholar 

  125. Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, et al. Regional activation of the cancer genome by long-range epigenetic remodeling. Cancer Cell. 2012;23(1):9–22.

    Article  PubMed  CAS  Google Scholar 

  126. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 2008;54(10):1600–7.

    Article  CAS  PubMed  Google Scholar 

  127. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 2011;21(3):502–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer. 2008;122(3):595–602.

    Article  CAS  PubMed  Google Scholar 

  129. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419(6907):624–9.

    Article  CAS  PubMed  Google Scholar 

  130. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer. 2006;45(7):639–45.

    Article  CAS  PubMed  Google Scholar 

  131. Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, et al. Polycomb-mediated silencing in neuroendocrine prostate cancer. Clin Epigenetics. 2015;7(1):40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  132. Xu K, ZJ W, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science. 2012;338(6113):1465–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, et al. Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. Am J Pathol. 2012;181(2):560–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001;61(11):4315–9.

    CAS  PubMed  Google Scholar 

  135. Heemers HV, Sebo TJ, Debes JD, Regan KM, Raclaw KA, Murphy LM, et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res. 2007;67(7):3422–30.

    Article  CAS  PubMed  Google Scholar 

  136. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol. 2004;204(2):159–66.

    Article  CAS  PubMed  Google Scholar 

  137. Halkidou K, Gnanapragasam VJ, Mehta PB, Logan IR, Brady ME, Cook S, et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 2003;22(16):2466–77.

    Article  CAS  PubMed  Google Scholar 

  138. Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell. 2013;4(5):331–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006;66(23):11341–7.

    Article  CAS  PubMed  Google Scholar 

  140. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436–9.

    Article  CAS  PubMed  Google Scholar 

  141. Ketscher A, Jilg CA, Willmann D, Hummel B, Imhof A, Russeler V, et al. LSD1 controls metastasis of androgen-independent prostate cancer cells through PXN and LPAR6. Oncogene. 2014;3:e120.

    Article  CAS  Google Scholar 

  142. Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, et al. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer. 2012;131(11):2704–9.

    Article  CAS  PubMed  Google Scholar 

  143. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98(3):604–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004;59(2):177–89.

    Article  CAS  PubMed  Google Scholar 

  145. Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics. 2008;3(6):300–9.

    Article  PubMed  PubMed Central  Google Scholar 

  146. Rathkopf DE, Picus J, Hussain A, Ellard S, Chi KN, Nydam T, et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;72(3):537–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Gryder BE, Akbashev MJ, Rood MK, Raftery ED, Meyers WM, Dillard P, et al. Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors. ACS Chem Biol. 2013;8(11):2550–60.

    Article  CAS  PubMed  Google Scholar 

  148. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res. 2007;67(11):5318–27.

    Article  CAS  PubMed  Google Scholar 

  149. Chinaranagari S, Sharma P, Bowen NJ, Chaudhary J. Prostate cancer epigenome. Methods Mol Biol. 2015;1238:125–40.

    Article  PubMed  Google Scholar 

  150. Valdes-Mora F, Song JZ, Statham AL, Strbenac D, Robinson MD, Nair SS, et al. Acetylation of H2A.Z is a key epigenetic modification associated with gene deregulation and epigenetic remodeling in cancer. Genome Res. 2012;22(2):307–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausio J. Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. Cancer Lett. 2012;315(1):38–47.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Prof Susan J. Clark and Dr. Hui-Ming Lin for their careful review of the manuscript. FVM is a National Breast Cancer Foundation/Cure Cancer Australia Foundation Postdoctoral Training Fellow. CS is supported by the National Health and Medical Research Council (NHMRC1070418). This work is supported by the National Health and Medical Research Council project grants (NHMRC 1063560 and NHMRC1070418).

Author information

Authors and Affiliations

  1. Histone Variant Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, Australia

    Fátima Valdés-Mora B.Sc., Ph.D.

  2. St. Vincent’s Clinical School, UNSW Sydney, Sydney, Australia

    Fátima Valdés-Mora B.Sc., Ph.D. & Clare Stirzaker B.Sc. (Honours), Ph.D.

  3. Epigenetic Deregulation Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, Australia

    Clare Stirzaker B.Sc. (Honours), Ph.D.

Authors
  1. Fátima Valdés-Mora B.Sc., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clare Stirzaker B.Sc. (Honours), Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fátima Valdés-Mora B.Sc., Ph.D. .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA

    Brian D. Robinson

  2. Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York, USA

    Juan Miguel Mosquera

  3. Institute for Academic Medicine, Houston Methodist Hospital Pathology and Genomic Medicine, Weill Medical College of Cornell University, Houston, Texas, USA

    Jae Y. Ro

  4. Institute for Academic Medicine, Houston Methodist Hospital Pathology and Genomic Medicine, Weill Medical College of Cornell University, Houston, Texas, USA

    Mukul Divatia

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Valdés-Mora, F., Stirzaker, C. (2018). Epigenetic Alterations in Primary Prostate Cancer. In: Robinson, B., Mosquera, J., Ro, J., Divatia, M. (eds) Precision Molecular Pathology of Prostate Cancer. Molecular Pathology Library. Springer, Cham. https://doi.org/10.1007/978-3-319-64096-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64096-9_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64094-5

  • Online ISBN: 978-3-319-64096-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation